RGEN
the council passes — AVOIDREPLIGEN CORP·Healthcare
The quality and the price don't line up.
45/100D
Price at last run$136as of Jul 8, 2026
healthcareFat operating margins39% operating margin — pricing power / a real moat hint.
GrowingRevenue growing ~35%.
Clean balance sheetLow leverage (debt/equity 0.00).
Catalystnone yet
✕Why not
The honest case against — what most tools hideMain riskvaluation stretched
Demanding valuationTrading at ~158× earnings — little room for error.
Quality concernReturns on capital are below what we want to own.
What keeps us out
- Paying up here — we'd want a better entry price.
- Growth slowing while the multiple stays rich.
Patience price & distance
as of Jul 8, 2026 runThe patience price is where value discipline would let the council in — deliberately strict: we'd rather miss ten winners than own one loser.
Catalyst
none yet
A catalyst is a plausible reason the gap could close — never a certainty.